
    
      MYELAXAT trial is multicentre, open trial which aims to evaluate the incidence of venous
      thromboembolic event (VTE) and the incidence of hemorrhagic complications. All patients with
      Myeloma treated with iMiDs and require thromboprophylaxis for 6 months, using an oral anti-Xa
      anticoagulant, Apixaban, in a preventive scheme, 2.5 mg x2/day
    
  